Frontlight ResearchEarly access
Taking people in United StatesPhase 3
Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)
Key facts
- Who runs it
- Bausch Health Americas, Inc.
- Where
- Albuquerque, Ann Arbor, Atlanta, Augusta, Aurora, Baltimore, Birmingham, Boston, Camden, Chapel Hill, Charleston, Charlotte, Charlottesville, Chattanooga, Chicago, Cleveland, Columbus, Dallas, Denton, Detroit, Durham, Edinburg, Fort Worth, Fresno, Gainesville, Hershey, Houston, Huntington, Indianapolis, Iowa City, Jacksonville, Kansas City, La Jolla, Las Vegas, Lebanon, Lexington, Los Angeles, Louisville, Madison, Manhasset, Maywood, Miami, Minneapolis, Mobile, Murray, Nashville, New Haven, New Orleans, New York, Newark, Orlando, Palo Alto, Philadelphia, Phoenix, Pittsburgh, Portland, Redwood City, Richmond, Rochester, Sacramento, Salt Lake City, San Antonio, Seattle, Tampa, Temple, The Bronx, Valhalla, Washington D.C., and Worcester, United StatesSee the 98 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 350 people, planned
- Started
- 29 Jan 2026
- Expected to end
- Feb 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Larsucosterol
- Placebo
- Record updated
- 12 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 33 criteriaShow less
Who can take part
- A participant will be eligible for inclusion in this study if he/she meets all the following criteria:
- Able to provide written informed consent (either from participant or participant's legally acceptable representative)
- Onset of jaundice within 8 weeks before hospital admission
- Average daily consumption of greater than (>) 40 (females) or >60 (males) grams alcohol for 6 months or longer, with less than (<) 8 weeks of abstinence before the onset of jaundice. Judgment regarding daily and long-term alcohol use and onset of jaundice will be made and documented by the site Investigator
- The determination of AH will be based on typical serum chemistry (as determined by local laboratory):; Serum total bilirubin >3.0 milligrams per deciliter (mg/dL) (required at randomization); ALT <400 international unit per Liter (IU/L) (required at randomization); 50 <AST <400 IU/L; AST <400 IU/L (required at randomization); AST >50 IU/L (at any time since current hospital admission or leading to this current hospitalization); AST/ALT >1.5 (at any time since current hospital admission or leading to this current hospitalization)
- Maddrey discriminant function (MDF) >=32, assuming a control prothrombin time of 12 seconds; NOTE: If a local laboratory's control time differs from 12 seconds, then the local laboratory's control time should be used. If control time is not stated or is stated as a range, the control time should be calculated by the formula prothrombin time/INR
- Original Model for End-stage Liver Disease (MELD; not MELD-Na) score: 21-30 (inclusive)
- Male or female participants 18 years of age or older
- Women of child-bearing potential (defined as females who are not surgically sterile or who are not over the age of 52 and amenorrheic for at least 12 months) must utilize appropriate birth control throughout the 90-day portion of the study. Acceptable methods that may be used are abstinence, birth control pills ("The Pill") or patch, diaphragm, IUD (coil), vaginal ring, condom, surgical sterilization or progestin implant or injection, or sexual activity limited to a sterile (e.g., vasectomized) male partner
- Male participants must agree to use a medically acceptable method of contraception/birth control and refrain from sperm donation throughout the 90-day portion of the study
- Participants must agree to participate in an alcohol abstinence support program recommended by the local institution's addiction specialists
- Participants must be dosed within 9 calendar days (216 hours) of hospital admission inclusive of time spent in other hospital(s)
Who cannot take part
- Participants using systemic corticosteroids for current AH before enrollment or having a history of using systemic corticosteroids for more than 8 days in the last 30 days prior to screening; NOTE: Inhaled, topical, or local corticosteroid injections are permitted NOTE: A participant who has a confirmed diagnosis of hypoadrenalism and is taking a physiological replacement dose of hydrocortisone (or equivalent) is permitted to take part in the trial
- A history of pre-admission refractory ascites defined as more than 4 paracenteses in the previous 8 weeks despite diuretic therapy
- Other concomitant cause(s) of liver disease as a result of:; Autoimmune liver disease; Ischemic hepatitis; Wilson disease or alpha 1 antitrypsin deficiency; Vascular liver disease (e.g., Budd-Chiari); Drug induced liver disease; Surface antigen positive hepatitis B (HBsAg+). NOTE: Participants with isolated core antibody (anti-HBc) or who are on stable antiviral medication with known viral suppression are not excluded, but appropriate HBV prophylaxis should be considered if steroid dosing >4 weeks is anticipated; Acute hepatitis A (if test performed per SOC); Acute HCV or chronic hepatitis C with a history of decompensated cirrhosis. NOTE: participants with stable chronic HCV or successfully treated HCV are not excluded; Acute hepatitis E (if test performed per SOC); Acute cytomegalovirus (CMV) viral hepatitis (if test performed per SOC)
- Participant listed for liver transplant (LT) prior to study drug administration
- Participants experiencing or considered at high risk for alcohol withdrawal seizures or delirium tremens
- Active infection (such as spontaneous bacterial peritonitis [SBP], urinary tract infection [UTI], cellulitis, pneumonia, bacteremia, acute viral hepatitis, uncontrolled HIV, and active SARS CoV2 infection); Participants who are febrile with leukocytosis are also excluded until active infection has been excluded to the satisfaction of the PI in consultation with the medical monitor; Participants with bacterial infections may be enrolled provided they remain in the enrollment window and the infection is adequately treated. For example, participants with bacterial peritonitis may be considered for enrollment once the infection has been treated and follow up paracentesis confirms the absence of SBP; Participants with systemic fungal infection of any kind cannot be considered for this trial
- Gastrointestinal bleeding not controlled by local therapy (i.e., band ligation or injection sclerotherapy). Participant who are at high risk of rebleeding or likely in need of TIPS insertion should be excluded
- Any known active malignancy or any malignancy diagnosed within the last five years other than curable skin cancer (basal cell or squamous cell carcinomas)
- History of organ transplantation other than corneal transplant
- Underlying disease that, in the opinion of the site Investigator, might be complicated or exacerbated by proposed treatments or might confound assessment of study drug
- Serum creatinine >2.5 mg/dL
- Participants with medical conditions that are expected to pose a high risk of short-term (less than or equal to [<=] 90 days) mortality unrelated to alcohol-associated hepatitis, or that may confound assessment of 90-day survival in the Investigator's judgement. Examples include, but are not limited to:; Severe concomitant cardiopulmonary disease (e.g., New York Heart Association [NYHA] Class III or IV heart failure); Clinically significant cardiac arrhythmia (e.g., sustained ventricular tachycardia, unmanaged atrial fibrillation, QTc >=500 msec, or high-grade AV block); Ventilator-dependent respiratory failure, or Global Initiative for Chronic Obstructive Lung Disease [GOLD] Stage III or IV chronic obstructive pulmonary disease [COPD]); End-stage renal disease requiring chronic, ongoing dialysis; Severe uncontrolled endocrine or metabolic disorders; Severe psychiatric illness likely to interfere with study participation; Hypotension/shock as defined by the North American Consortium for the study of End-stage Liver Disease (NACSELD) criteria (i.e., Mean Arterial Pressure [MAP] <60 millimeter of mercury (mmHg), despite adequate fluid resuscitation and cardiac output)
- A participant will be excluded from the study if he or she meets any of the following criteria:
- Participants undergoing continuous veno-venous hemodialysis (CVVH)
- TIPS insertion or variceal embolization within the last 4 weeks
- Known portal vein occlusion
- Liver biopsy (if carried out) with findings not compatible with AH. NOTE: A post-dose liver biopsy that is not compatible with AH will not be considered a protocol deviation
- Stage >=3 hepatic encephalopathy by West Haven criteria
- Existing or intended pregnancy or breast feeding
- Participation in another interventional clinical trial within 30 days of Screening
- Concern of participant's willingness and ability to be compliant with the schedule of protocol assessments, per the Investigator's judgement
Where in United States
- University of New Mexico (UNM) HospitalAlbuquerque, United StatesContact: Varsha Bhatt, PhDTaking people
- University of MichiganAnn Arbor, United StatesContact: Varsha Bhatt, PhDTaking people
- Emory University HospitalAtlanta, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- Piedmont Atlanta Hospital/Piedmont Transplant InstituteAtlanta, United StatesContact: Varsha Bhatt, PhDTaking people
- Augusta UniversityAugusta, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- University of Colorado Anschutz Medical CampusAurora, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- Johns Hopkins HospitalBaltimore, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- Mercy Medical Center - The Institute for Digestive Health and Liver DiseaseBaltimore, United StatesContact: Varsha Bhatt, PhDTaking people
- University of Alabama at Birmingham (UAB) HospitalBirmingham, United StatesContact: Varsha Bhatt, PhDTaking people
- Beth Israel Deaconess Medical CenterBoston, United StatesContact: Varsha Bhatt, PhDTaking people
- Boston University School of MedicineBoston, United StatesContact: Varsha Bhatt, PhDTaking people
- Massachusetts General HospitalBoston, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- Tufts Medical CenterBoston, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- Virtua Medical Group (VMG) - Virtua Center for Liver Disease - Toms RiverCamden, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- University of North Carolina (UNC) HospitalsChapel Hill, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- Medical University of South CarolinaCharleston, United StatesContact: Varsha Bhatt, PhDTaking people
- Ralph H. Johnson Department of Veterans Affairs Medical CenterCharleston, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- Levine Cancer Institute - Atrium HealthCharlotte, United StatesContact: Varsha Bhatt, PhDTaking people
- University of Virginia HealthCharlottesville, United StatesContact: Varsha Bhatt, PhDTaking people
- Galen Medical Group - Galen HepatologyChattanooga, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- Northwestern University Feinberg School of MedicineChicago, United StatesContact: Varsha Bhatt, PhDTaking people
- Rush University Medical CenterChicago, United StatesContact: Varsha Bhatt, PhDTaking people
- Cleveland ClinicCleveland, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- University Hospitals Cleveland Medical Center*Cleveland, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- The Ohio State University Wexner Medical Center (OSUWMC)Columbus, United StatesContact: Varsha Bhatt, PhDTaking people
- Baylor Scott White Research Institute - DallasDallas, United StatesContact: Varsha Bhatt, PhDTaking people
- The Liver Institute at Methodist Dallas Medical CenterDallas, United StatesContact: Varsha Bhatt, PhDTaking people
- North Texas GastroenterologyDenton, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- Henry Ford Hospital SystemDetroit, United StatesContact: Varsha Bhatt, PhDTaking people
- Duke University HospitalDurham, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- DHR Health Institute for Research and DevelopmentEdinburg, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- Baylor Scott & White All Saints Medical Center - Fort WorthFort Worth, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- Fresno Clinical Research Center (FCRC)Fresno, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- University of Florida (UF)Gainesville, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- Penn State Health Milton S. Hershey Medical CenterHershey, United StatesContact: Varsha Bhatt, PhDTaking people
- Baylor College of Medicine (BCM) - Baylor ClinicHouston, United StatesContact: Varsha Bhatt, PhDTaking people
- Clinical Trial Network - HoustonHouston, United StatesContact: Varsha Bhatt, PhDTaking people
- Houston Methodist Academic Medicine Associates - Hepatology - Texas Medical CenterHouston, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- Marshall HealthHuntington, United StatesContact: Varsha Bhatt, PhDTaking people
- Indiana Institute for Medical Research (Indiana VA)Indianapolis, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- IU Health University HospitalIndianapolis, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- University of Iowa Hospitals & ClinicsIowa City, United StatesContact: Varsha Bhatt, PhDTaking people
- Mayo ClinicJacksonville, United StatesContact: Varsha Bhatt, PhDTaking people
- Saint Luke's Hospital of Kansas CityKansas City, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- ScrippsLa Jolla, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- UC San Diego School of MedicineLa Jolla, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- University of Nevada Las VegasLas Vegas, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- Dartmouth Hitchcock Medical CenterLebanon, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- Kentucky Neuroscience Institute - University of Kentucky (UK) HealthCare (Kentucky Clinic)Lexington, United StatesContact: Varsha Bhatt, PhDTaking people
- University of Kentucky Chandler Medical CenterLexington, United StatesContact: Varsha Bhatt, PhDTaking people
- Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Varsha Bhatt, PhDTaking people
- UCLA Health - Ronald Reagan Medical CenterLos Angeles, United StatesContact: Varsha Bhatt, PhDTaking people
- Robley Rex VA Medical CenterLouisville, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- University of Wisconsin - MadisonMadison, United StatesContact: Varsha Bhatt, PhDNo longer taking part
- Northwell Health Physician Partners Sandra Atlas Bass Center for Liver DiseasesManhasset, United StatesContact: Varsha Bhatt, PhDTaking people
- Loyola University Medical Center (LUMC)Maywood, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- Reliant Medical ResearchMiami, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- University of MiamiMiami, United StatesContact: Varsha Bhatt, PhDTaking people
- University of Minnesota Medical CenterMinneapolis, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- University of South AlabamaMobile, United StatesContact: Varsha Bhatt, PhDTaking people
- USA Helath Digestive Health CenterMobile, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- Intermountain Transplant ClinicMurray, United StatesContact: Varsha Bhatt, PhDTaking people
- Vanderbilt University Medical CenterNashville, United StatesContact: Varsha Bhatt, PhDTaking people
- Yale School of MedicineNew Haven, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- Tulane University Health Sciences Center - Tulane AvenueNew Orleans, United StatesContact: Varsha Bhatt, PhDTaking people
- Columbia University Medical Center (CUMC) - Presbyterian Hospital and Vanderbilt ClinicNew York, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- NewYork-Presbyterian Weill Cornell Medical CenterNew York, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- NYU Langone HealthNew York, United StatesContact: Varsha Bhatt, PhDTaking people
- Rutgers University New Jersey Medical SchoolNewark, United StatesContact: Varsha Bhatt, PhDTaking people
- AdventHealth Transplant InstituteOrlando, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- Sutter HealthPalo Alto, United StatesContact: Varsha Bhatt, PhDTaking people
- Einstein Medical Center PhiladelphiaPhiladelphia, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- Temple University HospitalPhiladelphia, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- Thomas Jefferson University HospitalPhiladelphia, United StatesContact: Varsha Bhatt, PhDTaking people
- University of Pennsylvania HospitalPhiladelphia, United StatesContact: Varsha Bhatt, PhDTaking people
- VA Medical Center - PhiladelphiaPhiladelphia, United StatesContact: Varsha Bhatt, PhDTaking people
- Banner - University Medical Center, Phoenix, ArizonaPhoenix, United StatesContact: Varsha Bhatt, PhDTaking people
- Mayo Clinic PhoenixPhoenix, United StatesContact: Varsha Bhatt, PhDTaking people
- University of PittsburghPittsburgh, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- Maine Medical Center-Bramhall CampusPortland, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- Oregon Health Science UniversityPortland, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- Stanford Medicine - Clinical and Translational Research Unit - Redwood CityRedwood City, United StatesContact: Varsha Bhatt, PhDTaking people
- Bon Secours Liver Institute of RichmondRichmond, United StatesContact: Varsha Bhatt, PhDTaking people
- Richmond VA Medical CenterRichmond, United StatesContact: Varsha Bhatt, PhDTaking people
- University of Rochester Medical CenterRochester, United StatesContact: Varsha Bhatt, PhDTaking people
- University of California at Davis Medical CenterSacramento, United StatesContact: Varsha Bhatt, PhDTaking people
- University of Utah Health - University of UtahSalt Lake City, United StatesContact: Varsha Bhatt, PhDTaking people
- Methodist Healthcare - Methodist Hospital Specialty and TransplantSan Antonio, United StatesContact: Varsha Bhatt, PhDTaking people
- Swedish Medical CenterSeattle, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- UW Medicine - Harborview Medical CenterSeattle, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- Virginia Mason Medical Center (VMMC) - SeattleSeattle, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- AdventHealth Medical CampusTampa, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- Tampa General HospitalTampa, United StatesContact: Varsha Bhatt, PhDTaking people
- Baylor Scott White Research Institute - TempleTemple, United StatesContact: Varsha Bhatt, PhDTaking people
- Montefiore Medical CenterThe Bronx, United StatesContact: Varsha Bhatt, PhDTaking people
- Westchester Medical CenterValhalla, United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- Georgetown University Medical CenterWashington D.C., United StatesContact: Varsha Bhatt, PhDNot yet recruiting
- UMass Memorial Medical Center - University CampusWorcester, United StatesContact: Varsha Bhatt, PhDTaking people
About the trial
What the trial wants to find out
The primary purpose of this study is to evaluate the safety and efficacy of larsucosterol, as determined by transplant-free survival through Day 90 in participants with severe alcohol-associated hepatitis (AH) with pre-treatment Maddrey Discriminant Function (MDF) score greater than or equal to (>=) 32 and Model for End-stage Liver Disease (MELD) scores 21-30, inclusive.
The 2 groups in the trial
- Larsucosterol 30 mgTreatment being tested
Participants will receive Larsucosterol 30 milligrams (mg) intravenous infusion on Day 1.
Treatment: Larsucosterol
- PlaceboPlacebo, for comparison
Participants will receive intravenous infusion of placebo matched to Larsucosterol on Day 1.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- RE-AHFIRM (RandomizEd Study of Larsucosterol in Alcohol-associated Hepatitis to Confirm saFety and effIcacy of tReatMent)
- Record updated
- 12 November 2026